Sign In
Buy ARWR
$82.00
+0.180 (+0.220%)
At Close: Jun 22, 2026
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
01:10pm, Tuesday, 23'rd Nov 2021 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In Inherited Metabolic Disord
4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout
11:23am, Tuesday, 23'rd Nov 2021 The Motley Fool
The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.
4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout
06:23am, Tuesday, 23'rd Nov 2021
The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q4 2021 Results - Earnings Call Transcript
04:12am, Tuesday, 23'rd Nov 2021 Seeking Alpha
Arrowhead Pharmaceuticals, inc (ARWR) Q4 2021 Earnings Call Transcript
02:30am, Tuesday, 23'rd Nov 2021 The Motley Fool
ARWR earnings call for the period ending September 30, 2021.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2021 Earnings Call Transcript
12:06am, Tuesday, 23'rd Nov 2021 AlphaStreet
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) Q4 2021 earnings call, dated Nov. 22, 2021. Presentation: Operator Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout todays recorded presentation, all [] The post Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2021 Earnings Call Transcript first appeared on AlphaStreet .
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q4 2021 Results - Earnings Call Transcript
11:12pm, Monday, 22'nd Nov 2021
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q4 2021 Results - Earnings Call Transcript
Shares of RNAi Drug Companies Pop After Novo Lays Out $3.3 Billion for Dicerna
10:48pm, Monday, 22'nd Nov 2021 GuruFocus
Arrowhead and Alnylam up by 8% each Related Stocks: NVO , DRNA , LLY , MRK , ALNY , ARWR , NVS , ALXN , RHHBY ,
Arrowhead Pharmaceuticals EPS misses by $0.77, misses on revenue
09:03pm, Monday, 22'nd Nov 2021 Seeking Alpha
Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
09:01pm, Monday, 22'nd Nov 2021 Business Wire
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results and hosts a webcast to discuss the year
Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
09:00pm, Monday, 22'nd Nov 2021 Business Wire
Arrowhead Pharmaceuticals and GlaxoSmithKline sign exclusive license agreement for RNAi candidate ARO-HSD against NASH
Biotech ETFs
07:29pm, Monday, 22'nd Nov 2021 The Motley Fool
Here are the five best biotech ETFs to invest in right now.
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
08:04pm, Sunday, 21'st Nov 2021 Benzinga
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reportin
Arrowhead Pharmaceuticals FY 2021 Earnings Preview
10:35pm, Friday, 19'th Nov 2021 Seeking Alpha
